Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial

Document Type : Original Article


1 Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran


Background: This study evaluated the clinical efficacy and tolerability of a 14-day course of bismuth-based quadruple therapy including tinidazole and levofloxacin in compare to a 14-day bismuth-based quadruple therapy including clarithromycin as first-line treatment for Helicobacter pylori infection in Iranian adults. Materials and Methods: The study was a prospective, parallel group, randomized controlled, clinical trial that conducted on 150 patients with H. pylori infection. Patients were randomly assigned to the two groups as follows: first group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and clarithromycin 500 mg (PBAC group), and other group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, tinidazole 500 mg for 7 days, followed by levofloxacin 500 mg for the second 7 days (PBATL group). Main outcomes were eradication rate, tolerance of treatment, and dyspepsia severity. Results: The eradication rates for PBAC regimen was 81.1% (95% confidence interval [CI]: 71.9–90.2) and for PBATL regimen was 70.8% (95% CI: 60.1–81.6), which was not significantly different (P = 0.147). Tolerance of treatment was similar between groups. The median of severity of dyspeptic after treatment in PBAC group was 10 [9–14.75], which was similar to PBATL group 10 [9–13.5] (P = 0.690). Conclusion: There is no significant difference between PBAC and PBATL regimen, and efficacy was similar in both groups. The overall rate of treatment failure suggests that up to 18%–30% of patients will fail bismuth-based quadruple therapy and require retreatment for the infection.


McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.  Back to cited text no. 1
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012;13:607-15.  Back to cited text no. 2
Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299-304.  Back to cited text no. 3
Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010;15 Suppl 1:1-6.  Back to cited text no. 4
Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017;153:420-9.  Back to cited text no. 5
Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C, et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;19:131-4.  Back to cited text no. 6
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.  Back to cited text no. 7
Dib J Jr., Alvarez B, Mendez L, Cruz ME. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol 2013;14:123-5.  Back to cited text no. 8
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.  Back to cited text no. 9
Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143:55-610.  Back to cited text no. 10
Shah A, Javid G, Zargar SA, Teli F, Khan BA, Yattoo GN, et al. Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. Indian J Gastroenterol 2013;32:32-6.  Back to cited text no. 11
Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: A randomized clinical trial. Helicobacter 2012;17:43-8.  Back to cited text no. 12
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 11;(12): CD008337.  Back to cited text no. 13
Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection – The maastricht IV/florence consensus report. Gut 2012;61:646-64.  Back to cited text no. 14
Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The short-form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther 2007;25:477-86.  Back to cited text no. 15
Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.  Back to cited text no. 16
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.  Back to cited text no. 17
Warrington E, López-Román O, Tirado Montijo R, Urbina R, Cruz-Correa M, Toro DH, et al. Neither 10- nor 14-day sequential treatment is better than standard triple therapy for Helicobacter pylori eradication.P R Health Sci J 2016;35:203-8.  Back to cited text no. 18
Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet 2013;381:205-13.  Back to cited text no. 19
Ergül B, Doǧan Z, Sarikaya M, Filik L. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: A prospective study. Helicobacter 2013;18:454-8.  Back to cited text no. 20
Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G, et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859.  Back to cited text no. 21
Masoodi M, Panahian M, Rezadoost A, Heidari A. Eradication rate of Helicobacter pylori using a two-week quadruple therapy: A Report from Southern Iran. Middle East J Dig Dis 2013;5:81-5.  Back to cited text no. 22
Bahremand S, Nematollahi LR, Fourutan H, Tirgari F, Nouripour S, Mir E, et al. Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: A randomized clinical trial. Eur J Gastroenterol Hepatol 2006;18:511-4.  Back to cited text no. 23
Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H pylori eradication in Iran. World J Gastroenterol 2006;12:4553-6.  Back to cited text no. 24
Aminian K, Farsad F, Ghanbari A, Fakhreih S, Hasheminasab SM. A randomized trial comparing four Helicobacter pylori eradication regimens: Standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy. Trop Gastroenterol 2010;31:303-7.  Back to cited text no. 25
Metanat HA, Valizadeh SM, Fakheri H, Maleki I, Taghvaei T, Hosseini V, et al. Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication: A Randomized clinical trial. Helicobacter 2015;20:299-304.  Back to cited text no. 26
Cai W, Zhou L, Ren W, Deng L, Yu M. Variables influencing outcome of Helicobacter pylori eradication therapy in South China. Helicobacter 2009;14:91-6.  Back to cited text no. 27
Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA, et al. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo 2001;56:11-6.  Back to cited text no. 28